Silence Therapeutics Plc Reports A loss After Tax Of £8.2 Million In H1 FY19

  • Sep 12, 2019 BST
  • Team Kalkine

Silence Therapeutics Plc (AIM: SLN) for the six months ended 30 June 2019, has reported a loss after tax of £8.2 million as compared to a loss after tax of £8.7 million in H1 2018. Net cash outflow of the company from operating activities increased to £10.3 million as compared to £8.8 million in H1 2018. Cash and cash equivalents and term deposits stood at £16.5 million, while it was £26.5 million in FY 2018.

On 12th September 2019, at the time of writing, GMT 12.28 PM, SLN shares were trading at GBX 187.00, down by 6.00 points or 3.11% against the previous day closing price.

With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities. 

Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?

Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.

We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.

To know more about these dividend stocks, click here

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK